Follow us:

MedWatch Safety Alerts

MedWatch Safety Alert RSS Feed

FDA MedWatch Safety Alerts

Material in the patient's bloodstream can result in serious adverse health consequences such as the development of blood clots, embolism of the excess material to vital organs, or death.
Posted: June 21, 2017, 6:00 pm
There is a reasonable probability that the patient may experience adverse events, ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis.
Posted: June 17, 2017, 2:00 am
Accuracy errors may lead to patient deaths, serious or life-threatening injuries, and inaccurate, aborted, or prolonged medical procedures Posted 06/15/2017
Posted: June 15, 2017, 4:00 am
A patient may experience adverse events ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis. Posted 06/16/2017
Posted: June 15, 2017, 4:00 am
Failed dissolution could result in less drug being absorbed. Posted 06/15/2017
Posted: June 15, 2017, 4:00 am
An extreme and unexpected reduction in dose than expected could lead to a delay in treatment, disruption of clinical care of the patient, and worsening of patient’s conditions. Posted 06/15/2017
Posted: June 15, 2017, 4:00 am
The possibility of decreased quality and consistency of the product, may have an impact on the safety and efficacy of the product posing a risk to patients.
Posted: June 14, 2017, 7:42 pm
Patients should not stop taking Eliquis without consulting with their physician
Posted: June 13, 2017, 6:50 pm
UPDATED 06/06/2017. Class I Recall expanded. Falsely lower test results may lead to improper patient management and treatment for lead exposure or poisoning.
Posted: June 6, 2017, 11:00 am
Higher than allowed levels of harmful chemicals may cause chronic infections, long-term hospitalization due to additional surgical procedures, paralysis, and death. Posted 05/30/2017
Posted: May 30, 2017, 5:00 pm
Oral contraceptive tablets that are taken out of sequence may place the user at risk for contraceptive failure and unintended pregnancy.
Posted: May 29, 2017, 11:25 pm
Unintentional dosing with Zurampic has the potential to lead to adverse renal effects including acute renal failure.
Posted: May 26, 2017, 2:39 pm
Presence of sildenafil and tadalafil may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels.
Posted: May 26, 2017, 12:19 pm
Dietary supplements containing ephedrine alkaloids pose a risk of serious adverse events, including heart attack, stroke, and death.
Posted: May 25, 2017, 12:20 pm
A slow or improper driveline changeover places certain patients at risk of serious injury or death.
Posted: May 23, 2017, 9:06 pm
Use or consumption of products containing SARMs and anabolic steroid-like substances may cause acute liver injury, which is known to be a possible harmful effect of using steroid containing products.
Posted: May 22, 2017, 6:50 pm
Unexpected stop in ventilation therapy may cause serious adverse health consequences, including death.
Posted: May 22, 2017, 5:30 pm
Health care professionals should continue to limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary, and assess the necessity of repetitive MRIs with GBCAs.
Posted: May 22, 2017, 1:00 pm
Potential risks associated with balloon inflation and deflation difficulties include air embolism, additional intervention, thrombosis, and myocardial infarction.
Posted: May 16, 2017, 3:00 pm